PGRMC1: A new biomarker for the estrogen receptor in breast cancer

Research output: Contribution to journalEditorial

34 Scopus citations


Estrogen receptor (ER) status is a critical biomarker in breast cancer, in large part because the ER is the target of tamoxifen and similar drugs. In the previous issue of Breast Cancer Research, Neubauer and colleagues used a proteomic approach to identify proteins that are differentially regulated by ER in breast tumors. The authors showed that ER-negative tumors have elevated levels of PGRMC1 (progesterone receptor membrane component-1), a hormone receptor component and binding partner for P450 proteins. In contrast, PGRMC1 was phosphorylated in ER-positive tumors. The staining patterns of ER and PGRMC1 were mutually exclusive in breast tumor sections, and PGRMC1 staining was sharply increased in hypoxic areas of the tumor. The results suggest that PGRMC1 is a candidate biomarker for ER status and hypoxia in breast cancer.

Original languageEnglish
Article number113
JournalBreast Cancer Research
Issue number6
StatePublished - Nov 24 2008

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PGRMC1: A new biomarker for the estrogen receptor in breast cancer'. Together they form a unique fingerprint.

Cite this